利用历史血嗜酸性粒细胞计数指导慢阻肺治疗决策
本文讨论影响慢阻肺患者血嗜酸性粒细胞计数(BEC)的因素,回顾如何用历史BEC指导治疗决策,并提出4种BEC表型分组以帮助精准分层选择吸入糖皮质激素或生物制剂。目前尚无关于BEC低高阈值及测量频率的共识。
要点
- 高达40%的慢阻肺患者病程中曾出现BEC≥300 cells/μL。
- BEC可识别2型炎症慢阻肺患者,作为加用ICS或生物制剂的候选。
- 提出4种BEC表型分组:持续≥300、间歇≥300、100-300、持续<100 cells/μL。
核心结论
- 历史BEC结合临床特征可支持更个性化的慢阻肺治疗决策。
研究设计与样本
- 本文为How I Do It类型文章,基于临床经验和现有文献提出观点。
主要发现
- 真实世界和临床试验数据显示慢阻肺伴2型炎症患者的BEC随时间变化。
- 高达40%的慢阻肺患者病程中曾出现BEC≥300 cells/μL。
关键数值与推荐
- 提出4种BEC表型分组: predominantly ≥300 cells/μL、间歇≥300 cells/μL、100-300 cells/μL、 predominantly <100 cells/μL。
- 目前尚无关于慢阻肺BEC低高阈值或测量频率/次数的共识。
临床怎么用
- 单次BEC测量简单且常足以识别高水平2型炎症患者。
- 重复BEC结合临床特征可能支持更个性化的慢阻肺管理。
- 识别BEC模式有助于精准分层选择加用ICS或生物制剂。
局限性
- 目前尚无关于BEC阈值和测量频率的共识。
- 基于临床经验和现有文献提出分组,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Up to 40% of patients with COPD have evidence of elevated eosinophil counts ≥ 300 cells/μL at some point during their disease. Blood eosinophil counts (BECs) are a biomarker that can identify patients with COPD and type 2 inflammation who are candidates for add-on inhaled corticosteroids (ICSs) or biologic therapy. Evidence from real-world and clinical trial data shows variation in BECs over time in patients with COPD and type 2 inflammation. This How I Do It article discusses factors that can influence eosinophil counts, reviews how the use of historical eosinophil counts can inform treatment decisions, and provides practical considerations for identifying underlying type 2 inflammation in patients with COPD in the clinic. Currently, there is no consensus on what constitutes "low" or "high" BEC in COPD or the frequency or number of eosinophil measurements needed to effectively guide disease management. Based on our experience from the clinic and available literature, we propose 4 broad phenotypic groups of patients with COPD: those with BECs predominantly ≥ 300 cells/μL, intermittently ≥ 300 cells/μL, within an intermediate range of 100 to 300 cells/μL, and those with BECs predominantly < 100 cells/μL. Identifying these patterns can help with more precise stratification for pharmacologic interventions, such as adding ICSs or biologic therapies. Although single BEC measurements are easy to obtain and often sufficient to identify patients with COPD and high levels of type 2 inflammation, when interpreted alongside clinical characteristics, repeated BECs may be able to support a more personalized approach to COPD care.
引用
- Bafadhel M, Martinez FJ, Criner GJ, et al. Using Historical Blood Eosinophil Counts to Guide Treatment Decisions in Patients With COPD. Chest. 2026. PMID: 42501940. doi:10.1016/j.chest.2026.06.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。